Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InspireMD (NSPR) Cash & Equivalents (2016 - 2025)

InspireMD's Cash & Equivalents history spans 16 years, with the latest figure at $8.9 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 52.74% year-over-year to $8.9 million; the TTM value through Dec 2025 reached $8.9 million, down 52.74%, while the annual FY2025 figure was $8.9 million, 52.74% down from the prior year.
  • Cash & Equivalents reached $8.9 million in Q4 2025 per NSPR's latest filing, down from $63.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $63.4 million in Q3 2025 to a low of $3.9 million in Q3 2022.
  • Average Cash & Equivalents over 5 years is $17.1 million, with a median of $11.8 million recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: surged 1301.91% in 2021, then plummeted 84.57% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $12.0 million in 2021, then plummeted by 61.41% to $4.6 million in 2022, then soared by 108.12% to $9.6 million in 2023, then skyrocketed by 96.22% to $18.9 million in 2024, then tumbled by 52.74% to $8.9 million in 2025.
  • Per Business Quant, the three most recent readings for NSPR's Cash & Equivalents are $8.9 million (Q4 2025), $63.4 million (Q3 2025), and $11.5 million (Q2 2025).